ARO-ANG3
AROANG1001
Phase 1 small_molecule completed
Quick answer
ARO-ANG3 for Dyslipidemias is a Phase 1 program (small_molecule) at ARROWHEAD PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ARROWHEAD PHARMACEUTICALS, INC.
- Indication
- Dyslipidemias
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed